Plasma prostacyclin levels in Behçet's disease. 1985

N Hizli, and G Sahin, and F Sahin, and E Kansu, and S Duru, and S Karacadag, and F Batman, and S Dundar, and T Zileli, and H Telatar

UI MeSH Term Description Entries
D008297 Male Males
D011464 Epoprostenol A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from PROSTAGLANDIN ENDOPEROXIDES in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension (HYPERTENSION, PULMONARY). Prostacyclin,Prostaglandin I2,Epoprostanol,Epoprostenol Sodium,Epoprostenol Sodium Salt, (5Z,9alpha,11alpha,13E,15S)-Isomer,Flolan,Prostaglandin I(2),Veletri
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001528 Behcet Syndrome Rare chronic inflammatory disease involving the small blood vessels. It is of unknown etiology and characterized by mucocutaneous ulceration in the mouth and genital region and uveitis with hypopyon. The neuro-ocular form may cause blindness and death. SYNOVITIS; THROMBOPHLEBITIS; gastrointestinal ulcerations; RETINAL VASCULITIS; and OPTIC ATROPHY may occur as well. Behcet Disease,Behcet's Disease,Behcet's Syndrome,Triple-Symptom Complex,Adamantiades-Behcet Disease,Behcet Triple Symptom Complex,Behçet Disease,Old Silk Route Disease,Triple Symptom Complex,Adamantiades Behcet Disease,Adamantiades-Behcet Diseases,Behçet Diseases,Symptom Complex, Triple,Triple Symptom Complices

Related Publications

N Hizli, and G Sahin, and F Sahin, and E Kansu, and S Duru, and S Karacadag, and F Batman, and S Dundar, and T Zileli, and H Telatar
August 1985, Lancet (London, England),
N Hizli, and G Sahin, and F Sahin, and E Kansu, and S Duru, and S Karacadag, and F Batman, and S Dundar, and T Zileli, and H Telatar
January 1997, Clinical rheumatology,
N Hizli, and G Sahin, and F Sahin, and E Kansu, and S Duru, and S Karacadag, and F Batman, and S Dundar, and T Zileli, and H Telatar
May 2003, Rheumatology international,
N Hizli, and G Sahin, and F Sahin, and E Kansu, and S Duru, and S Karacadag, and F Batman, and S Dundar, and T Zileli, and H Telatar
February 1998, The Journal of rheumatology,
N Hizli, and G Sahin, and F Sahin, and E Kansu, and S Duru, and S Karacadag, and F Batman, and S Dundar, and T Zileli, and H Telatar
November 1997, Clinical rheumatology,
N Hizli, and G Sahin, and F Sahin, and E Kansu, and S Duru, and S Karacadag, and F Batman, and S Dundar, and T Zileli, and H Telatar
January 2000, Dermatology (Basel, Switzerland),
N Hizli, and G Sahin, and F Sahin, and E Kansu, and S Duru, and S Karacadag, and F Batman, and S Dundar, and T Zileli, and H Telatar
November 1986, Lancet (London, England),
N Hizli, and G Sahin, and F Sahin, and E Kansu, and S Duru, and S Karacadag, and F Batman, and S Dundar, and T Zileli, and H Telatar
January 2007, The Journal of dermatological treatment,
N Hizli, and G Sahin, and F Sahin, and E Kansu, and S Duru, and S Karacadag, and F Batman, and S Dundar, and T Zileli, and H Telatar
April 2012, Journal of the neurological sciences,
N Hizli, and G Sahin, and F Sahin, and E Kansu, and S Duru, and S Karacadag, and F Batman, and S Dundar, and T Zileli, and H Telatar
January 2000, Japanese journal of ophthalmology,
Copied contents to your clipboard!